NICE wants more data for lung cancer treatment Iressa
This article was originally published in Scrip
NICE, the health technology appraisal body for England and Wales, has asked AstraZeneca for more information about its Iressa (gefitinib) for treating non-small-cell lung cancer (NSCLC). Meanwhile, the firm's submission to NICE marks a first for patient access schemes.
You may also be interested in...
Brazil’s medicines regulator, ANVISA, finally has a new set of rules for the evaluation and marketing authorization of advanced therapy medicines.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.